CStone Pharmaceuticals

CStone Pharmaceuticals a biopharmaceutical company researches develops and commercializes immunooncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally It offers Sugemalimab a monoclonal antibody against programmed death PD ligand 1 GAVRETO an RET inhibitor for the treatment of patients with advanced or metastatic RETmutant medullary and RET fusionpositive thyroid cancers and avapritinib a KITPDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation The companys product pipeline includes Nofazinlimab a PD1 antibody for the treatment of patients with hepatocellular carcinoma Ivosidenib an isocitrate dehydrogenase 1 IDH1 inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation and Fisogatinib an FGFR4 inhibitor to treat hepatocellular carcinoma Its products also comprise CS1002 CS2006 CS3002 CS3005 CS2007 CS2008 and CS500 for solid tumors and CS5001 for solid tumors and hematologic malignancies The company was incorporated in 2015 and is headquartered in Shanghai China